Source-grounded facts extracted from Fulcrum Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Greg Tourangeau departed as Vice President, Finance and principal accounting officer at Fulcrum Therapeutics, Inc..
“On June 10, 2026, Fulcrum and Greg Tourangeau, Fulcrum’s Vice President, Finance and principal accounting officer, mutually agreed that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed between Mr. Tourangeau and Fulcrum.”
Fulcrum Therapeutics, Inc. announced a restructuring with charges of approximately $4.2 million (approximately 85%, from 57 full-time employees to 9 full-time employees).
“On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD. The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees, and is expected to be substantially completed during the second quarter of 2026. Fulcrum expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs.”
Fulcrum Therapeutics, Inc. reported first quarter of 2026 results: net income $18.9 million.
“higher employee compensation costs, including $0.3 million of increased stock-based compensation expense, as well as higher professional services costs. • Net Loss: Net loss was $18.9 million for the three months ended March 31, 2026, compared to a net loss of $17.7 million for the three months ended March 31, 2025. Cash Runway Guidance Based on its current operating”
Fulcrum Therapeutics, Inc. terminated CAMP4 License with CAMP4 Therapeutics Corp. (effective 2026-04-23).
“On April 23, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, provided written notice to CAMP4 Therapeutics Corp., or CAMP4, of termination of the License Agreement dated July 5, 2023, between Fulcrum and CAMP4, or the CAMP4 License, which termination will be effective in accordance with the terms of such agreement.”
Fulcrum Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co. (effective 2025-12-10).
“On December 10, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement, or the Underwriting Agreement, with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering”
Rachel King was appointed as director at Fulcrum Therapeutics, Inc..
“On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.”
James J. Collins resigned as director at Fulcrum Therapeutics, Inc..
“On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.”
Fulcrum Therapeutics, Inc. announced a restructuring with charges of approximately $2.0 million affecting Company (reduction of the Company's workforce from 80 to 51 full-time employees).
“On September 24, 2024, Fulcrum announced the approval by its board of directors of a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of Diamond-Blackfan anemia, and its early discovery programs. The plan will reduce the Company's workforce from 80 to 51 full-time employees, including a reduction of positions across both research and development and general and administrative. Fulcrum expects to incur one-time costs of approximately $2.0 million in connection with this workforce reduction, primarily related to cash payments for severance.”
Colin Hill was elected as Class I Director at Fulcrum Therapeutics, Inc..
“elected Colin Hill as a member of the Board, effective June 17, 2024”
Fulcrum Therapeutics, Inc. reported first quarter of 2024 results: net income Net loss was $26.9 million for the three months ended March 31, 2024. Guidance reaffirmed.
“Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024”
Fulcrum Therapeutics, Inc. entered into a collaboration with Genzyme Corporation, a wholly-owned subsidiary of Sanofi valued at $80.0 million (effective 2024-05-11).
“On May 11, 2024, Fulcrum Therapeutics, Inc., or Fulcrum, entered into a collaboration and license agreement with Genzyme Corporation, a wholly-owned subsidiary of Sanofi, or Sanofi, pursuant to which Fulcrum granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod, an oral small molecule for the treatment of facioscapulohumeral muscular dystrophy, or FSHD, outside of the United States.”
Fulcrum Therapeutics, Inc. reported fourth quarter and full year of 2023 results: revenue $0.9 million, net income $(24.8) million.
“offering completed in January 2023 of $117.3 million, partially offset by our net cash used in operating activities in 2023. • Collaboration Revenue: Collaboration revenue was $0.9 million for the fourth quarter of 2023 as compared to $0.7 million for the fourth quarter of 2022. The increase of $0.2 million was attributable to an increase in revenues under our”
Fulcrum Therapeutics, Inc. reported third quarter of 2023 results: revenue $0.8 million, net income $24.0 million.
“cash, cash equivalents, and marketable securities were $257.1 million, as compared to $202.9 million as of December 31, 2022. • Collaboration Revenue: Collaboration revenue was $0.8 million for the third quarter of 2023 as compared to $1.2 million for the third quarter of 2022. • R&D Expenses: Research and development expenses were $18.2 million for the third”
Mel Hayes changed role as Executive Vice President, Patient Experience at Fulcrum Therapeutics, Inc..
“On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum’s current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer. Mr. Hayes agreed to remain with Fulcrum as its Executive Vice President, Patient Experience, and in connection therewith, entered into an amended and restated employment agreement reflecting his new role and title at Fulcrum.”
Fulcrum Therapeutics, Inc. reported financial results for the second quarter of 2023.
“On August 3, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter ended June 30, 2023.”
Alan A. Musso was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..
“On August 2, 2023, Fulcrum’s board of directors, or the Board, appointed Alan A. Musso as Fulcrum’s chief financial officer and treasurer, effective August 7, 2023.”
Fulcrum Therapeutics, Inc. entered into License Agreement with CAMP4 Therapeutics Corporation (effective 2023-07-05).
“On July 5, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, entered into a license agreement with CAMP4 Therapeutics Corporation, or CAMP4”
Fulcrum Therapeutics, Inc.: Amendment to Restated Certificate of Incorporation to limit liability of certain officers as permitted by recent amendments to Delaware law (effective 2023-06-08).
“At the 2023 annual meeting of stockholders of Fulcrum Therapeutics, Inc., or Fulcrum, held on June 8, 2023, or the Annual Meeting, the stockholders of Fulcrum approved an amendment to Fulcrum’s Restated Certificate of Incorporation to limit the liability of certain officers of Fulcrum as permitted by recent amendments to Delaware law. The certificate of amendment of Fulcrum’s Restated Certificate of Incorporation, or Certificate of Amendment, was filed with the Secretary of State of the State of Delaware on June 8, 2023 and became effective upon filing.”
Fulcrum Therapeutics, Inc. reported quarter ended March 31, 2023 results: net income Net loss was $24.8 million.
“Collaboration revenue was $0.3 million for the first quarter of 2023 as compared to $2.6 million for the first quarter of 2022.”
Robert E. Gould changed role as principal executive officer and principal financial officer at Fulcrum Therapeutics, Inc..
“Mr. Sapir will succeed Dr. Gould as principal executive officer and as principal financial officer effective July 1, 2023. Dr. Gould will remain on the Board as a class III director.”
Alex C. Sapir was appointed as class II director at Fulcrum Therapeutics, Inc..
“On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.”
Alex C. Sapir was appointed as President and Chief Executive Officer at Fulcrum Therapeutics, Inc..
“On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.”
Robert E. Gould was appointed as principal financial officer at Fulcrum Therapeutics, Inc..
“On May 11, 2023, in recognition of the duties he is performing and the vacancy in the chief financial officer position, Fulcrum’s board of directors, or the Board, appointed Robert E. Gould, current interim president and chief executive officer, as principal financial officer, with immediate effect.”
Esther Rajavelu resigned as Chief Financial Officer at Fulcrum Therapeutics, Inc..
“On March 31, 2023, Esther Rajavelu notified Fulcrum Therapeutics, Inc., or Fulcrum, of her intent to resign as chief financial officer and treasurer (and as principal financial officer), effective April 21, 2023, to pursue another opportunity.”
Fulcrum Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2022.
“On March 9, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter and year ended December 31, 2022.”
Fulcrum Therapeutics, Inc. entered into underwriting agreement with Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as representatives of the several underwriters valued at approximately $117.3 million (effective 2023-01-17).
“On January 17, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement with Goldman Sachs & Co. LLC, SVB Securities LLC and Piper Sandler & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 9,615,384 shares of its common stock, par value $0.001 per share, at a price to the public of $13.00 per share, less underwriting discounts and commissions.”
Robert J. Gould was appointed as Interim President and Chief Executive Officer at Fulcrum Therapeutics, Inc..
“On January 3, 2023, the board of directors of Fulcrum, or the Board, appointed Robert J. Gould, former chief executive officer and president and current Class III director, as interim president and chief executive officer and as Fulcrum’s principal executive officer, effective January 3, 2023.”
Bryan Stuart changed role as president, chief executive officer and Class II director at Fulcrum Therapeutics, Inc..
“On January 2, 2023, Bryan Stuart and Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed that he would transition from his role as president, chief executive officer and as Class II director”
Fulcrum Therapeutics, Inc. reported the third quarter of 2022 results: revenue $1.2 million, net income Net loss was $23.7 million.
“Third Quarter 2022 Financial Results • Cash Position: As of September 30, 2022, cash, cash equivalents, and marketable securities were $221.8 million as compared to $218.2 million as of December 31, 2021. The increase in cash is primarily tied to our equity offering in August 2022, partially offset by our net cash used in operating activities. • Collaboration Revenue: Collaboration revenue was $1.2 million for the third quarter of 2022 as compared to $4.9 million for the third quarter of 2021. The decrease of $3.7 million was primarily due to the winding down of Fulcrum's collaboration agreement with Acceleron Pharma Inc., a wholly owned subsidiary of Merck & Co., Inc. • Operating Expenses: Total operating expenses were $25.5 million for the third quarter of 2022 as compared to $25.7 million for the third quarter of 2021. A decrease of $1.7 million in R&D expenses was primarily due to reduced discovery and external research and development costs. This was partially offset by an increas”
Judith A. Dunn resigned as president, research and development at Fulcrum Therapeutics, Inc..
“Dr. Judith A. Dunn entered into a separation agreement subsequent to Dr. Dunn’s resignation from her position as president, research and development.”
Mel Hayes changed role as Chief Operating Officer at Fulcrum Therapeutics, Inc..
“On August 11, 2022, Fulcrum Therapeutics, Inc., or Fulcrum, announced that its board of directors promoted Mel Hayes, its current chief commercial officer, to the position of chief operating officer effective August 9, 2022, such date the Effective Date.”
Chris Morabito, M.D. resigned as Chief Medical Officer at Fulcrum Therapeutics, Inc..
“On July 8, 2022, Chris Morabito, M.D., Chief Medical Officer of Fulcrum Therapeutics, Inc., or Fulcrum, notified Fulcrum of his resignation from this position and from his employment with Fulcrum, to be effective on July 13, 2022, in order to pursue a new opportunity.”
Gregory Tourangeau was appointed as Principal Accounting Officer at Fulcrum Therapeutics, Inc..
“Fulcrum appointed Mr. Gregory Tourangeau, Fulcrum’s Controller, as principal accounting officer effective March 11, 2022.”
Peter Thomson was terminated as Principal Accounting Officer at Fulcrum Therapeutics, Inc..
“On March 4, 2022, Fulcrum Therapeutics, Inc. (“Fulcrum”) notified Mr. Peter Thomson of the elimination of the Vice President, Finance & Accounting position and, as a consequence, the termination of his role as Fulcrum’s principal accounting officer, effective as of March 11, 2022.”
Kate Haviland was named as Chair at Fulcrum Therapeutics, Inc..
“On January 10, 2022, the Company announced that Kate Haviland has been named Chair of the Board.”
Mark Levin resigned as Executive Chairman at Fulcrum Therapeutics, Inc..
“On January 5, 2022, Mark Levin notified the Company of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective April 18, 2022.”
Peter Thomson changed role as Principal Financial Officer at Fulcrum Therapeutics, Inc..
“As a result of Ms. Rajavelu’s appointment, Peter Thomson, the Company’s Vice President, Finance and Accounting, will cease to serve as principal financial officer.”
Esther Rajavelu was appointed as Chief Financial Officer and Treasurer at Fulcrum Therapeutics, Inc..
“On January 3, 2022, the Board of Directors (the “Board”) of Fulcrum Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Treasurer, effective immediately.”
Sonja Banks was elected as Director at Fulcrum Therapeutics, Inc..
“elected Sonja Banks as a member of the Board, effective December 8, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.